Re-Use of Established Drugs for Anti-Metastatic Indications

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2016 Jan 16

PMID 26771645

Citations 3

Authors

Frank Entschladen

Dane A Thyssen

David W Drell

Affiliations

Soon will be listed here.

Abstract

Most patients that die from cancer do not die due to the primary tumor but due to the development of metastases. However, there is currently still no drug on the market that specifically addresses and inhibits metastasis formation. This lack was, in the past, largely due to the lack of appropriate screening models, but recent developments have established such models and have provided evidence that tumor cell migration works as a surrogate for metastasis formation. Herein we deliver on several examples a rationale for not only testing novel cancer drugs by use of these screening assays, but also reconsider established drugs even of other fields of indication.

Citing Articles

Agonist Effects of Propranolol on Non-Tumor Human Breast Cells.

Gargiulo L, Rivero E, Di Siervi N, Buzzi E, Buffone M, Davio C Cells. 2020; 9(4).

PMID: 32331276 PMC: 7226086. DOI: 10.3390/cells9041036.

Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview.

Brivio S, Cadamuro M, Fabris L, Strazzabosco M Gene Expr. 2017; 18(1):31-50.

PMID: 29070148 PMC: 5860940. DOI: 10.3727/105221617X15088670121925.

Cell adhesion heterogeneity reinforces tumour cell dissemination: novel insights from a mathematical model.

Reher D, Klink B, Deutsch A, Voss-Bohme A Biol Direct. 2017; 12(1):18.

PMID: 28800767 PMC: 5553611. DOI: 10.1186/s13062-017-0188-z.

References

Palm D, Lang K, Brandt B, Zaenker K, Entschladen F . In vitro and in vivo imaging of cell migration: two interdepending methods to unravel metastasis formation. Semin Cancer Biol. 2005; 15(5):396-404. DOI: 10.1016/j.semcancer.2005.06.008. View

Giampieri R, Scartozzi M, Del Prete M, Faloppi L, Bianconi M, Ridolfi F . Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer. Medicine (Baltimore). 2015; 94(24):e719. PMC: 4616528. DOI: 10.1097/MD.0000000000000719. View

Grytli H, Fagerland M, Fossa S, Tasken K, Haheim L . Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate. 2012; 73(3):250-60. DOI: 10.1002/pros.22564. View

Mosadegh B, Lockett M, Minn K, Simon K, Gilbert K, Hillier S . A paper-based invasion assay: assessing chemotaxis of cancer cells in gradients of oxygen. Biomaterials. 2015; 52:262-71. DOI: 10.1016/j.biomaterials.2015.02.012. View

De Giorgi V, Gandini S, Grazzini M, Benemei S, Marchionni N, Geppetti P . Effect of β-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death. Mayo Clin Proc. 2013; 88(11):1196-203. DOI: 10.1016/j.mayocp.2013.09.001. View

Steeg P . Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006; 12(8):895-904. DOI: 10.1038/nm1469. View

Fernandes M, Rosel D, Brabek J . Translation in solid cancer: are size-based response criteria an anachronism?. Clin Transl Oncol. 2014; 17(1):1-10. DOI: 10.1007/s12094-014-1207-5. View

Masur K, Lang K, Niggemann B, Zanker K, Entschladen F . High PKC alpha and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. Mol Biol Cell. 2001; 12(7):1973-82. PMC: 55643. DOI: 10.1091/mbc.12.7.1973. View

Kim B, Hannanta-Anan P, Chau M, Kim Y, Swartz M, Wu M . Cooperative roles of SDF-1α and EGF gradients on tumor cell migration revealed by a robust 3D microfluidic model. PLoS One. 2013; 8(7):e68422. PMC: 3711811. DOI: 10.1371/journal.pone.0068422. View

10.

Lemeshow S, Sorensen H, Phillips G, Yang E, Antonsen S, Riis A . β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2011; 20(10):2273-9. PMC: 3652234. DOI: 10.1158/1055-9965.EPI-11-0249. View

11.

Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, Brown E, Lee R, Meric-Bernstam F . Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011; 29(19):2645-52. PMC: 3139371. DOI: 10.1200/JCO.2010.33.4441. View

12.

Palm D, Lang K, Niggemann B, Drell 4th T, Masur K, Zaenker K . The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer. 2005; 118(11):2744-9. DOI: 10.1002/ijc.21723. View

13.

Lang K, Drell 4th T, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker K . Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer. 2004; 112(2):231-8. DOI: 10.1002/ijc.20410. View

14.

Jeon J, Bersini S, Gilardi M, Dubini G, Charest J, Moretti M . Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation. Proc Natl Acad Sci U S A. 2014; 112(1):214-9. PMC: 4291627. DOI: 10.1073/pnas.1417115112. View

15.

Beedie S, Peer C, Pisle S, Gardner E, Mahony C, Barnett S . Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues. Mol Cancer Ther. 2015; 14(10):2228-37. PMC: 4596783. DOI: 10.1158/1535-7163.MCT-15-0320. View

16.

Ortega A . A new role for GABA: inhibition of tumor cell migration. Trends Pharmacol Sci. 2003; 24(4):151-4. DOI: 10.1016/S0165-6147(03)00052-X. View

17.

Choi C, Song T, Kim T, Choi J, Park J, Yoon A . Meta-analysis of the effects of beta blocker on survival time in cancer patients. J Cancer Res Clin Oncol. 2014; 140(7):1179-88. DOI: 10.1007/s00432-014-1658-7. View

18.

Wang H, Liao Z, Komaki R, Welsh J, OReilly M, Chang J . Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol. 2013; 24(5):1312-9. PMC: 3629895. DOI: 10.1093/annonc/mds616. View

19.

Watkins J, Thaker P, Nick A, Ramondetta L, Kumar S, Urbauer D . Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. 2015; 121(19):3444-51. PMC: 4575637. DOI: 10.1002/cncr.29392. View

20.

Medinger M, Halter J, Heim D, Buser A, Gerull S, Stern M . Angiogenic markers in plasma cell myeloma patients treated with novel agents. Anticancer Res. 2015; 35(2):1085-90. View